207 related articles for article (PubMed ID: 26988747)
1. Efficacy of rasagiline in early Parkinson's disease: a meta-analysis of data from the TEMPO and ADAGIO studies.
Hauser RA; Abler V; Eyal E; Eliaz RE
Int J Neurosci; 2016 Oct; 126(10):942-6. PubMed ID: 26988747
[TBL] [Abstract][Full Text] [Related]
2. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes.
Rascol O; Fitzer-Attas CJ; Hauser R; Jankovic J; Lang A; Langston JW; Melamed E; Poewe W; Stocchi F; Tolosa E; Eyal E; Weiss YM; Olanow CW
Lancet Neurol; 2011 May; 10(5):415-23. PubMed ID: 21482191
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of rasagiline for the treatment of Parkinson's disease: an updated meta-analysis.
Chang Y; Wang LB; Li D; Lei K; Liu SY
Ann Med; 2017 Aug; 49(5):421-434. PubMed ID: 28293967
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of adjunctive rasagiline in Japanese Parkinson's disease patients with wearing-off phenomena: A phase 2/3, randomized, double-blind, placebo-controlled, multicenter study.
Hattori N; Takeda A; Takeda S; Nishimura A; Kato M; Mochizuki H; Nagai M; Takahashi R
Parkinsonism Relat Disord; 2018 Aug; 53():21-27. PubMed ID: 29748109
[TBL] [Abstract][Full Text] [Related]
5. Rasagiline: a review of its use in the treatment of idiopathic Parkinson's disease.
Hoy SM; Keating GM
Drugs; 2012 Mar; 72(5):643-69. PubMed ID: 22439669
[TBL] [Abstract][Full Text] [Related]
6. Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan.
Hattori N; Takeda A; Takeda S; Nishimura A; Kitagawa T; Mochizuki H; Nagai M; Takahashi R
Parkinsonism Relat Disord; 2019 Mar; 60():146-152. PubMed ID: 30205936
[TBL] [Abstract][Full Text] [Related]
7. Rasagiline for mild cognitive impairment in Parkinson's disease: A placebo-controlled trial.
Weintraub D; Hauser RA; Elm JJ; Pagan F; Davis MD; Choudhry A;
Mov Disord; 2016 May; 31(5):709-14. PubMed ID: 27030249
[TBL] [Abstract][Full Text] [Related]
8. Symptomatic efficacy of rasagiline monotherapy in early Parkinson's disease: post-hoc analyses from the ADAGIO trial.
Jankovic J; Berkovich E; Eyal E; Tolosa E
Parkinsonism Relat Disord; 2014 Jun; 20(6):640-3. PubMed ID: 24637126
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, delayed-start trial of rasagiline in Parkinson's disease.
Olanow CW; Rascol O; Hauser R; Feigin PD; Jankovic J; Lang A; Langston W; Melamed E; Poewe W; Stocchi F; Tolosa E;
N Engl J Med; 2009 Sep; 361(13):1268-78. PubMed ID: 19776408
[TBL] [Abstract][Full Text] [Related]
10. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.
Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E;
Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996
[TBL] [Abstract][Full Text] [Related]
11. Long-term effects of rasagiline and the natural history of treated Parkinson's disease.
Rascol O; Hauser RA; Stocchi F; Fitzer-Attas CJ; Sidi Y; Abler V; Olanow CW;
Mov Disord; 2016 Oct; 31(10):1489-1496. PubMed ID: 27431201
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
13. Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO study: effects on nonmotor symptoms and tolerability.
Smith KM; Eyal E; Weintraub D;
JAMA Neurol; 2015 Jan; 72(1):88-95. PubMed ID: 25420207
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease.
Tolosa E; Stern MB
Eur J Neurol; 2012 Feb; 19(2):258-64. PubMed ID: 21819487
[TBL] [Abstract][Full Text] [Related]
15. Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.
Poewe W; Hauser RA; Lang A;
Mov Disord; 2015 Apr; 30(4):589-92. PubMed ID: 25545629
[TBL] [Abstract][Full Text] [Related]
16. Dopamine D2 receptor gene variants and response to rasagiline in early Parkinson's disease: a pharmacogenetic study.
Masellis M; Collinson S; Freeman N; Tampakeras M; Levy J; Tchelet A; Eyal E; Berkovich E; Eliaz RE; Abler V; Grossman I; Fitzer-Attas C; Tiwari A; Hayden MR; Kennedy JL; Lang AE; Knight J;
Brain; 2016 Jul; 139(Pt 7):2050-62. PubMed ID: 27190009
[TBL] [Abstract][Full Text] [Related]
17. The role of rasagiline in the treatment of Parkinson's disease.
Leegwater-Kim J; Bortan E
Clin Interv Aging; 2010 May; 5():149-56. PubMed ID: 20517484
[TBL] [Abstract][Full Text] [Related]
18. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
19. Effect of rasagiline as adjunct therapy to levodopa on severity of OFF in Parkinson's disease.
Stocchi F; Rabey JM
Eur J Neurol; 2011 Dec; 18(12):1373-8. PubMed ID: 21895884
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease.
Marconi S; Zwingers T
Eur Rev Med Pharmacol Sci; 2014 Jul; 18(13):1879-82. PubMed ID: 25010617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
